Enanta Pharmaceuticals (ENTA) News Today $9.08 -0.34 (-3.61%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below 200-Day Moving Average - Should You Sell?Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Passes Below 200 Day Moving Average - Here's WhyNovember 14, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of "Moderate Buy" by AnalystsEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one haNovember 6, 2024 | marketbeat.comAssenagon Asset Management S.A. Sells 282,755 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Assenagon Asset Management S.A. cut its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 66.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 143,806 shares of the biotechnology company'sNovember 2, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Sees Large Growth in Short InterestEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) was the target of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 3,430,000 shares, an increase of 14.7% from the September 30th total of 2,990,000 shares. Approximately 17.4% of the company's stock are sold short. Based on an average trading volume of 165,700 shares, the short-interest ratio is currently 20.7 days.October 29, 2024 | marketbeat.comThe past three years for Enanta Pharmaceuticals (NASDAQ:ENTA) investors has not been profitableOctober 27, 2024 | finance.yahoo.comEnanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Passes Below Two Hundred Day Moving Average - Here's What HappenedEnanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below Two Hundred Day Moving Average - Time to Sell?October 22, 2024 | marketbeat.comEnanta Pharmaceuticals (ENTA): Promising Clinical Stage Biotech with Robust PipelineOctober 19, 2024 | finance.yahoo.comMillennium Management LLC's Strategic Acquisition of Enanta Pharmaceuticals SharesOctober 17, 2024 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Position Lowered by AQR Capital Management LLCAQR Capital Management LLC trimmed its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 45.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 60,005 shares of the biotechnology company's stock afterOctober 14, 2024 | marketbeat.comDimensional Fund Advisors LP Trims Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Dimensional Fund Advisors LP decreased its holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 31.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 129,062 shares of the biotechnologyOctober 12, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has received a consensus rating of "Moderate Buy" from the five analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, two have issuOctober 12, 2024 | marketbeat.comBuy Rating Affirmed for Enanta Pharmaceuticals on Strong Clinical Trial Outcomes and Promising Pipeline ValuationOctober 10, 2024 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)HC Wainwright reaffirmed a "buy" rating and issued a $27.00 price target on shares of Enanta Pharmaceuticals in a report on Thursday.October 10, 2024 | marketbeat.comBuy Rating for Enanta Pharmaceuticals Amid Reduced Competition and Promising Drug TrialsOctober 9, 2024 | markets.businessinsider.comA Glimpse Into The Expert Outlook On Enanta Pharma Through 4 AnalystsOctober 9, 2024 | benzinga.comEnanta Pharmaceuticals (NASDAQ:ENTA) Receives Market Outperform Rating from JMP SecuritiesJMP Securities reissued a "market outperform" rating and issued a $22.00 price objective on shares of Enanta Pharmaceuticals in a report on Wednesday.October 9, 2024 | marketbeat.comEnanta Pharmaceuticals Gains Buy Rating on Strong Clinical Results for EDP-323September 28, 2024 | markets.businessinsider.comEnanta Pharmaceuticals Reports Antiviral For Respiratory Syncytial Virus Reduces Virus Levels, Symptoms In StudySeptember 27, 2024 | benzinga.comEnanta Pharmaceuticals (ENTA) Gets a Hold from Leerink PartnersSeptember 27, 2024 | markets.businessinsider.comEnanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)September 26, 2024 | businesswire.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Armistice Capital LLCArmistice Capital LLC lowered its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 11.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,096,000 shareSeptember 26, 2024 | marketbeat.comArdelyx, Inc. (41X.F)September 23, 2024 | sg.finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Short Interest Up 5.7% in AugustEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) saw a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 2,960,000 shares, a growth of 5.7% from the July 31st total of 2,800,000 shares. Currently, 15.0% of the shares of the company are short sold. Based on an average daily volume of 184,800 shares, the days-to-cover ratio is currently 16.0 days.September 3, 2024 | marketbeat.comEnanta Pharmaceuticals Inc.August 27, 2024 | barrons.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, twoAugust 23, 2024 | marketbeat.comAssenagon Asset Management S.A. Sells 157,097 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Assenagon Asset Management S.A. reduced its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 26.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 426,561 shares of the biotechnologyAugust 19, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Hyperfine (HYPR) and Biogen (BIIB)August 11, 2024 | markets.businessinsider.comEnanta Pharmaceuticals, Inc. (ENTA): Caligan Partners' Top Holding Right Now?August 9, 2024 | msn.comVanguard Group Inc. Boosts Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Vanguard Group Inc. increased its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 7.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,928,078 shares of the biotechnology company's stockAugust 9, 2024 | marketbeat.comBuy Rating Affirmed on Enanta Pharmaceuticals’ Promising Drug Pipeline and Strategic Expansion into ImmunologyAugust 8, 2024 | markets.businessinsider.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third QuarterAugust 6, 2024 | stockhouse.comEnanta Pharmaceuticals (NASDAQ:ENTA) Announces Earnings ResultsEnanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) posted its quarterly earnings data on Monday. The biotechnology company reported ($1.07) EPS for the quarter, beating the consensus estimate of ($1.43) by $0.36. The business had revenue of $17.97 million for the quarter, compared to analysts' expectations of $17.44 million. Enanta Pharmaceuticals had a negative net margin of 180.76% and a negative return on equity of 64.85%. The firm's revenue was down 4.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.27) EPS.August 6, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Sells 366,291 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)Jacobs Levy Equity Management Inc. reduced its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 65.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owneJuly 31, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of "Hold" by AnalystsEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has been given an average rating of "Hold" by the six research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two hJuly 29, 2024 | marketbeat.comShort Interest in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Rises By 9.1%Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) saw a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 3,010,000 shares, a growth of 9.1% from the June 15th total of 2,760,000 shares. Based on an average daily trading volume, of 164,700 shares, the short-interest ratio is presently 18.3 days. Approximately 15.3% of the company's stock are sold short.July 18, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Insider Scott T. Rottinghaus Sells 5,375 SharesJuly 16, 2024 | insidertrades.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Insider Sells $64,785.93 in StockJuly 16, 2024 | insidertrades.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Insider Sells $89,589.78 in StockJune 18, 2024 | insidertrades.comTara Lynn Kieffer Sells 7,266 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) StockEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) insider Tara Lynn Kieffer sold 7,266 shares of the stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $12.33, for a total transaction of $89,589.78. Following the transaction, the insider now owns 32,341 shares of the company's stock, valued at approximately $398,764.53. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.June 17, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Hold" by BrokeragesEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has earned a consensus rating of "Hold" from the six ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two havJune 9, 2024 | marketbeat.comEnanta Pharmaceuticals to Participate at the Jefferies Global Healthcare ConferenceMay 29, 2024 | businesswire.comQ3 2024 EPS Estimates for Enanta Pharmaceuticals, Inc. Decreased by HC Wainwright (NASDAQ:ENTA)Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Investment analysts at HC Wainwright decreased their Q3 2024 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a research report issued on Tuesday, May 7th. HC Wainwright analyst E. Arce now anticipates that the bMay 10, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Forecasted to Post Q1 2025 Earnings of ($1.15) Per ShareEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for Enanta Pharmaceuticals in a research note issued on Tuesday, May 7th. HC Wainwright analyst E. Arce forecasts that the biotechnology company will post earnings per share of ($1.15) forMay 9, 2024 | marketbeat.comEnanta Pharmaceuticals (NASDAQ:ENTA) Stock Rating Upgraded by StockNews.comStockNews.com upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday.May 9, 2024 | marketbeat.comBuy Rating Affirmed: Enanta Pharmaceuticals’ Clinical and Financial Prospects Bolster Investor ConfidenceMay 8, 2024 | markets.businessinsider.comEnanta Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 8, 2024 | finance.yahoo.comHold Rating on Enanta Pharmaceuticals Amidst Clinical Trials Uncertainty and Financial OutlookMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Enanta Pharmaceuticals Amidst Promising RSV Developments and Clinical Trial ExecutionMay 7, 2024 | markets.businessinsider.comEnanta Pharmaceuticals (NASDAQ:ENTA) Given New $27.00 Price Target at HC WainwrightHC Wainwright dropped their price objective on Enanta Pharmaceuticals from $28.00 to $27.00 and set a "buy" rating on the stock in a research note on Tuesday.May 7, 2024 | marketbeat.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call TranscriptMay 7, 2024 | finance.yahoo.com Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address 📉 Warning: Market Crash Predicted - Secure Your Savings (Ad)The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%. Take these 4 steps to protect your retirement here >>> ENTA Media Mentions By Week ENTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENTA News Sentiment▼0.000.45▲Average Medical News Sentiment ENTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENTA Articles This Week▼12▲ENTA Articles Average Week Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GNFT News Today PRTA News Today REPL News Today ERAS News Today AUTL News Today CGEM News Today CRGX News Today AVXL News Today TRDA News Today ABUS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENTA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
